We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

132 hedge funds and large institutions have $470M invested in Akebia Therapeutics in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $391K | Put options by funds: $185K

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

61% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 33

11% more funds holding

Funds holding: 119 → 132 (+13)

7.31% more ownership

Funds ownership: 63.98% → 71.29% (+7.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

21% less capital invested

Capital invested by funds: $593M → $470M (-$123M)

Holders
132
Holders Change
+13
Holders Change %
+10.92%
% of All Funds
2.99%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
53
Reduced
33
Closed
18
Calls
$391K
Puts
$185K
Net Calls
+$206K
Net Calls Change
-$1.77M

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$9.39M
2
Renaissance Technologies
Renaissance Technologies
New York
+$6.64M
3
PA
Perceptive Advisors
New York
+$5.93M
4
NHAS
Novo Holdings A/S
Denmark
+$5.6M
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.75M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$6.48M
2
First Manhattan
First Manhattan
New York
-$5.76M
3
EAM
Eagle Asset Management
Florida
-$5.43M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.7M
5
Two Sigma Investments
Two Sigma Investments
New York
-$3.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
26
Numeric Investors
Massachusetts
$3.25M -$2.63M -158,855 -42%
Marshall Wace
27
Marshall Wace
United Kingdom
$3.04M +$1.9M +114,349 +127%
Invesco
28
Invesco
Georgia
$2.93M -$6.48M -390,759 -66%
Bank of America
29
Bank of America
North Carolina
$2.86M -$1.94M -116,938 -38%
EI
30
EAM Investors
California
$2.68M -$912K -54,967 -23%
OAM
31
Oxford Asset Management
United Kingdom
$2.61M -$493K -29,708 -15%
Ameriprise
32
Ameriprise
Minnesota
$2.5M +$194K +11,706 +7%
Deutsche Bank
33
Deutsche Bank
Germany
$2.4M -$826K -49,800 -24%
PAM
34
Panagora Asset Management
Massachusetts
$2.18M +$1.93M +116,418 +386%
DCM
35
DAFNA Capital Management
California
$2.02M – – –
MOACM
36
Mutual of America Capital Management
New York
$1.94M +$311K +18,779 +17%
Wells Fargo
37
Wells Fargo
California
$1.8M +$531K +32,024 +36%
SIM
38
Spark Investment Management
New York
$1.73M +$1.4M +84,600 +266%
UBS Group
39
UBS Group
Switzerland
$1.72M +$655K +39,491 +52%
Alyeska Investment Group
40
Alyeska Investment Group
Illinois
$1.54M -$397K -23,914 -19%
PPA
41
Parametric Portfolio Associates
Washington
$1.42M -$161K -9,734 -9%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$1.25M +$96.2K +5,800 +7%
TA
43
Teachers Advisors
New York
$1.2M +$168K +10,131 +14%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.05M -$17.1K -1,029 -1%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$1.01M +$212K +12,755 +23%
HW
46
Hancock Whitney
Mississippi
$995K +$1.11M +66,900 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$956K +$1.07M +64,300 New
JIC
48
Johnson Investment Counsel
Ohio
$913K -$16.6K -1,000 -2%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$907K +$33.2K +2,000 +3%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$861K +$80.3K +4,840 +9%
1
2
3 4 5

AKBA Hedge Fund Activity: Q4 2017 in Review

132 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2017, worth a combined $470M — down 21% from $593M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new AKBA positions and 18 closed out — a net gain of 13 holders — while 53 added to existing stakes and 33 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $9.39M. The largest seller was Invesco, cutting an estimated $6.48M.

  • 132 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2017, up from 119 in Q3 2017.
  • Funds reported $470M of Akebia Therapeutics stock for Q4 2017, down 21% quarter-over-quarter.
  • 31 funds opened new Akebia Therapeutics positions in Q4 2017 and 18 closed out, a net change of +13 holders.
  • The largest Akebia Therapeutics buyer in Q4 2017 was Nantahala Capital Management, an estimated $9.39M added.
  • The largest Akebia Therapeutics seller in Q4 2017 was Invesco, an estimated $6.48M sold.

Based on aggregated 13F filings for Q4 2017.